Caricamento...
Expectations of Serious Adverse Events at the End-of-Life of Patients with Acute Myeloid Leukemia Who Receive Salvage Therapy
BACKGROUND: Patients with acute myeloid leukemia (AML) and refractory disease receive investigational therapies within 2 months of their death. The attribution of serious adverse events (AE) in this phase to disease progression versus drug toxicity is tenuous. We aimed to determine the incidences of...
Salvato in:
| Pubblicato in: | Clin Lymphoma Myeloma Leuk |
|---|---|
| Autori principali: | , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2013
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4341913/ https://ncbi.nlm.nih.gov/pubmed/23763918 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2013.03.021 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|